Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 284 clinical trials
Acute Pancreatitis Targets (APT) Study

The severity of acute pancreatitis varies considerably from minor symptoms to multi-organ failure. The pathophysiological mechanisms associated with these individual differences in severity are largely unknown. Acute pancreatitis is therefore classified based on clinical characteristics and routine blood samples. Information about pathophysiology and molecular subtypes of acute pancreatitis is needed …

  • 0 views
  • 04 Feb, 2021
  • 1 location
Prognostic Significance of Fatty Liver Disease in Bariatric Patients

and the control group (n=600) of age, weight and comorbidity matched patients who choose not to undergo bariatric surgery. The overall aim is to examine prevalence of the spectrum of fatty liver

fatty liver
bariatric surgery
liver disease
  • 0 views
  • 18 Mar, 2021
  • 1 location
The Olmsted NAFLD Epidemiology Study (TONES)

Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of

  • 0 views
  • 18 Feb, 2021
  • 1 location
Screening for NAFLD in Flanders

In the Belgian adult population more than half, and numbers are still increasing, of the population is overweight or obese. These people are at risk to develop NAFLD. However, we lack epidemiological data in Belgium. Therefore, it is important to do epidemiological studies to investigate NAFLD prevalence and disease severity …

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients

A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. 100 patients will be enrolled in a 100 mg open-label arm.

steatosis
mri-pdff
fibrosis
fibroscan
fatty liver
  • 237 views
  • 24 Jan, 2021
  • 68 locations
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.

Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide. The current strategy proposed by the EASL/EASO/EASD European

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

fibrosis
steatohepatitis
hepatic fibrosis
  • 72 views
  • 28 Apr, 2021
  • 297 locations
Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 (100 mg, 200 mg and 400 mg PO QD), compared with placebo, in NASH subjects with Stage 2, Stage 3 or Stage 4 fibrosis. This study is designed to …

steatohepatitis
fibrosis
hepatic fibrosis
fatty liver
liver disease
  • 452 views
  • 15 May, 2021
  • 133 locations
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide and is a major cause of cirrhosis and liver cancer in Western countries. Because of its

diabetes
diabetic complication
fibrosis
liver cancer
liver disease
  • 1 views
  • 05 Feb, 2021
  • 1 location
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

(Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.

diabetes
hba1c
fibrosis
liver disease
random plasma glucose
  • 58 views
  • 21 Jan, 2021
  • 1 location